Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.  The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.  Choi (necrotic) responses were more commonly observed in patients treated at higher doses.  In addition, intravenous infusion of JX-594 was safe and well-tolerated.  These data were presented today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington DC.

"These data represent a significant milestone for the field of oncology and viral therapy as this is the first time that a viral or genetic product has demonstrated reproducible, biopsy-proven delivery to multiple solid tumor types following intravenous administration," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We look forward to extending our experience with IV JX-594 in our planned Phase 3 trial in patients with advanced liver cancer.  This pivotal trial will utilize both IV and targeted intratumoral injections of JX-594 to maximize potential patient benefit.  We expect to initiate this study in Q4 of 2010."

"JX-594 represents a promising potential treatment option for patients with multiple types of cancer.  As the first intravenous biological immunotherapy to demonstrate safety and tumor-specific delivery, JX-594 may add significantly to the armamentarium for many solid tumors," stated '/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
(Date:8/27/2014)... MSC , a healthcare performance improvement company advancing clinical ... Mary Beth Loesch to President and CEO. ... companies for rapid growth and market expansion, Loesch joined ... Development and Healthcare. In that role, she oversaw MSC,s ... corporate strategy and marketing. Previously, Loesch served as Senior ...
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... United States and Canada and Monetary Damages, ... a medical device company focused on the treatment ... patent infringement lawsuits,against CryoCath Technologies Inc., one in ... Delaware and one in Canada., The lawsuits ...
... Preparing for the NFL, Combine Use SURGEX(TM) as part of ... ... Clubs(TM), BASKING RIDGE, N.J., Jan. 15 ... MBTG), announced today that SURGEX(TM) is,currently being administered as part of ...
... Jan. 15 As drastic cutbacks at ... challenge,blockbuster drug teams. Social networks have entered ... expenditures are being scrutinized for,ROI. Product recalls ... and,responsibilities on drug marketers. Yet new marketing ...
Cached Biology Technology:CryoCor Files Patent Infringement Lawsuits Against CryoCath 2CryoCor Files Patent Infringement Lawsuits Against CryoCath 3Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime 2Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime 3Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime 4Beyond DTC: Pharma Industry Faces New Challenges, Competition, Strategies for Market Dominance 2
(Date:8/27/2014)... traps are lost or abandoned each year in U.S. ... which continue to catch fish, crabs, and other species ... habitat, fisheries, and the watermen who depend on the ... published NOAA study. , The report, published in the ... its kind to examine the derelict fish trap problem, ...
(Date:8/27/2014)... A growing number of studies have shown ... the pathogenesis of Parkinson,s disease. Previous studies ... Medical University in China have shown that ... injury, reduced divalent metal transporter 1 expression, ... substantia nigra of rotenone-induced Parkinson,s disease rats. ...
(Date:8/27/2014)... Adelaide research has shown that piglets can be weaned ... , The outcome of the study at the University,s ... Science , is an important finding for pig producers. ... loss of production. , "Sows don,t usually start their ... after their piglets have been weaned," says Ms Alice ...
Breaking Biology News(10 mins):NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2Piglet weaning age no bar to litter frequency 2
... & Children,s Hospital and the University of Adelaide, Australia, ... with high blood pressure during pregnancy and pre-term birth. ... of Obstetrics & Gynaecology, are a major step forward ... blood pressure in pregnancy. The research has been ...
... balance of nature looms prominently in the public mind these ... declining fish stocks are but a few of the issues ... is it? It depends on whom you ask, ... the School of Life Sciences specializing in biology and society. ...
... no group takes credit. The pressure on the U.S. ... the president orders an attack, but it turns out ... Things go downhill from there. , To avoid that ... with extensive nuclear expertise, headed by Stanford physicist Michael ...
Cached Biology News:Herpes virus link to complications in pregnancy 2Managing uncertainty important in ecological balance: ASU researcher 2Group led by Stanford physicist says there's an urgent need for nuclear detectives 2Group led by Stanford physicist says there's an urgent need for nuclear detectives 3